
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics PLC is experiencing a positive outlook driven by its innovative therapeutic candidates, particularly BT8009 and BT5528, which have demonstrated promising efficacy and acceptable safety profiles in clinical trials for high-unmet-need indications such as urothelial and ovarian cancer. The company has enhanced its probability of success for BT8009 to 40% in various treatment settings, which bolsters its overall platform value and reflects confidence in its clinical development pipeline. Furthermore, the company's efficient drug selection process through its high throughput phage display screening platform positions it favorably within the competitive landscape, suggesting potential differentiation from existing therapies like Padcev.
Bears say
Bicycle Therapeutics PLC faces significant financial challenges, as highlighted by its bear case scenario indicating a potential 0% success rate for its product candidate BT8009, which could lead to a drastic reduction in platform value and a fair value of $9 per share based solely on cash. The company has reported disappointing clinical data for key oncology indications, while elevated selling, general, and administrative expenses of $21.6 million exceeded both internal and consensus estimates, further straining financial resources. Additionally, regulatory and commercial risks loom large, as the company's clinical assets could fail to demonstrate sufficient efficacy or safety, hindering approval timelines and diminishing sales potential amidst increasing competition.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares